Diabetes Research Treatment

It is not surprising that a large amount of companies have entered the field of diabetes research and treatment with so much money being spent on this disease. Most of the companies in the field of diabetes treatment and research are small microcaps, while many of these companies are NYSE and NASDAQ behemoths. Some of these companies are biotech firms that are developing medications for the treatment of diabetes and its related sequelae. Some corporations provide diabetic treatment supplies while others provide diabetic treatment services such as renal dialysis. Most of these companies are found on the OTCBB, but some are located on the pinks or the AMEX. One thing that each of these stocks has in common is huge potential. These stocks are microcaps in the most truthful sense of the word with market caps varying from one to three hundred million dollars.

Here, what we have is a market sector that is ripe for the picking when all is considered. Our intention is not to sound insensitive by suggesting that we attempt to profit from a terrible illness, but the matter of fact remains that this is a golden opportunity. Comprising a substantial portion of nation's health care costs we know from published data that diabetes is big business. The prevalence diabetes is expected to augment considerably over the next 5 decades as obesity rates climb and the Hispanic population grows. What we have just shown you are things that big business have known for years. Why do you think that there are so many companies scrambling for a piece of the diabetes market? As most of the companies in this market are microcaps, we expect one of three things to come about. Scenario one is that the company will never successfully develop their therapeutic medications and they will go out of business. Scenario two is that the company will show promise and will be acquired by a much larger biotech firm. Scenario three is that the company will be successful in their endeavors, ignore offers from larger firms, and move to a larger exchange in an effort to compete with these firms. Two of the three envisioned scenarios offer great promise for investors.

We will examine a microcap company that is poised to take advantage of the lucrative diabetes market.

Beginner Money Investing Diabetes Related Stocks Diabetes Stocks in Market Diabetes Research & Treatment Diabetes Microcap #1: Nutrition 21, Inc. (NASDAQ: NXXI)